
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Eagle Pharmaceuticals Inc (EGRX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: EGRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $17
1 Year Target Price $17
1 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.13% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.58M USD | Price to earnings Ratio 3.41 | 1Y Target Price 17 |
Price to earnings Ratio 3.41 | 1Y Target Price 17 | ||
Volume (30-day avg) 1 | Beta 0.62 | 52 Weeks Range 0.00 - 6.37 | Updated Date 06/30/2025 |
52 Weeks Range 0.00 - 6.37 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.64% | Operating Margin (TTM) 15.94% |
Management Effectiveness
Return on Assets (TTM) 6.63% | Return on Equity (TTM) 4.88% |
Valuation
Trailing PE 3.41 | Forward PE 11.34 | Enterprise Value 93839858 | Price to Sales(TTM) 0.15 |
Enterprise Value 93839858 | Price to Sales(TTM) 0.15 | ||
Enterprise Value to Revenue 0.36 | Enterprise Value to EBITDA 1.68 | Shares Outstanding 12958200 | Shares Floating 9305684 |
Shares Outstanding 12958200 | Shares Floating 9305684 | ||
Percent Insiders 11.64 | Percent Institutions 50.09 |
Analyst Ratings
Rating 1 | Target Price 17 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Eagle Pharmaceuticals Inc

Company Overview
History and Background
Eagle Pharmaceuticals Inc. was founded in 2007. It focuses on developing and commercializing injectable products, primarily in the areas of critical care and oncology.
Core Business Areas
- Proprietary Products: Development and commercialization of branded pharmaceutical products.
- Royalty and Contract Revenue: Receiving royalties and revenue from licensing agreements and contract manufacturing.
Leadership and Structure
The company is led by a management team with experience in pharmaceutical development and commercialization. The organizational structure includes departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- BENDEKA (bendamustine hydrochloride injection): A rapid infusion formulation of bendamustine, used to treat chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Competitors include generic bendamustine manufacturers.
- PEMFEXY (pemetrexed injection): A liquid, ready-to-dilute version of pemetrexed, a chemotherapy drug used to treat certain types of lung cancer and mesothelioma. Eagle Pharma has secured an exclusive license and royalty agreement for PEMFEXY. Competitors include generic pemetrexed manufacturers.
- BARDAFIL (deferoxamine mesylate for injection): Ready-to-use deferoxamine mesylate for injection. Competitors include generic deferoxamine mesylate manufacturers.
- LANDAU (oxaliplatin injection): Ready-to-dilute oxaliplatin injection. Competitors include generic oxaliplatin manufacturers.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition from both branded and generic drug manufacturers. The injectables market is a significant component, driven by oncology and critical care needs.
Positioning
Eagle Pharmaceuticals focuses on developing injectable products with improved formulations or delivery methods, aiming to provide clinical advantages and capture market share in niche therapeutic areas. The company aims to differentiate through faster administration, reduced side effects, or improved stability.
Total Addressable Market (TAM)
The injectables market is multi-billion USD. Eagle Pharmaceuticals focuses on specific segments within this TAM, aiming to capture a portion of the market with its differentiated products.
Upturn SWOT Analysis
Strengths
- Differentiated product formulations
- Focus on niche therapeutic areas
- Established partnerships and licensing agreements
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- Dependence on third-party manufacturers
- Exposure to generic competition
- Small Market Cap
Opportunities
- Expansion into new therapeutic areas
- Acquisition of complementary products or technologies
- Strategic partnerships for international expansion
- Regulatory approvals for new formulations
Threats
- Increased generic competition
- Patent challenges
- Changes in regulatory requirements
- Pricing pressures from payers
Competitors and Market Share
Key Competitors
- TEVA
- MYL
- PFE
- VRX
Competitive Landscape
Eagle Pharmaceuticals competes with both branded and generic pharmaceutical companies. Its competitive advantage lies in its differentiated product formulations and focus on niche therapeutic areas. However, it faces challenges from larger companies with greater resources and broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Requires access to historical financial data to analyze the company's growth trends.
Future Projections: Requires access to analyst reports and company guidance to provide projections for future growth.
Recent Initiatives: Requires access to company press releases and SEC filings to highlight recent strategic initiatives.
Summary
Eagle Pharmaceuticals is a niche pharmaceutical company focusing on injectable products with differentiated formulations. Its strength lies in its innovative products and targeted therapeutic areas, however, its reliance on a few products and exposure to generic competition present challenges. Future growth depends on successful product development, strategic partnerships, and navigating the competitive landscape. Financial stability and future profitability depends on its ability to maintain margins and expand its product pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated and may vary. Financial data needs to be obtained from latest quarterly and annual reports.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eagle Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Woodcliff Lake, NJ, United States | ||
IPO Launch date 2014-02-12 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 134 | Website https://www.eagleus.com |
Full time employees 134 | Website https://www.eagleus.com |
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.